CN1216613C - Health-care product capable of regulating blood-lipid and its preparation method - Google Patents
Health-care product capable of regulating blood-lipid and its preparation method Download PDFInfo
- Publication number
- CN1216613C CN1216613C CN 01113266 CN01113266A CN1216613C CN 1216613 C CN1216613 C CN 1216613C CN 01113266 CN01113266 CN 01113266 CN 01113266 A CN01113266 A CN 01113266A CN 1216613 C CN1216613 C CN 1216613C
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- ethanol
- health
- rhizoma alismatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 150000002632 lipids Chemical class 0.000 claims abstract description 17
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 15
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 15
- 235000020712 soy bean extract Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 230000036541 health Effects 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 235000015468 Lycium chinense Nutrition 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 229930003944 flavone Natural products 0.000 claims description 10
- 235000011949 flavones Nutrition 0.000 claims description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002212 flavone derivatives Chemical class 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims description 6
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims description 6
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000005202 decontamination Methods 0.000 claims description 3
- 230000003588 decontaminative effect Effects 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 241000748223 Alisma Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a health-care product having the function of regulating blood fat, and a preparation method thereof. The health-care product having the function of regulating blood fat, which is disclosed by the present invention, comprises active ingredients which are composed of 60 to 180 of hawkthorn extract, 40 to 120 of matrimony vine extract, 25 to 75 of alisma rhizome extract and 10 to 30 of soybean extract according to the proportion by weight. The health-care product having the function of regulating blood lipid has the function of blood lipid reduction in many aspects, such as synthesis of endogenous lipid decrease, lipidic transportation and excretion promotion, lipid metabolism regulation, etc. The health-care product having the function of regulating blood lipid has the advantages of exact efficiency, safety and reliability, and has good social benefit and economic benefit.
Description
Technical field
The present invention relates to field of health care products, be specifically related to a kind of health product and preparation method with blood lipid regulation effect.
Background technology
World Health Organization (WHO) divides five types six classes hyperlipemia.The hyperlipemia of China belongs to II type and IV type basically.II type hyperlipidemia patient, cholesterol level increases in the blood plasma, triglyceride increases in the IV type hyperlipidemia patient blood plasma, hyperlipidemia is easily brought out arteriosclerosis and coronary heart disease, especially gallbladder is liquor-saturated does not admittedly all increase the person with triglyceride, the danger of suffering from coronary heart disease is bigger, and the active treatment hyperlipemia is one of important measures of prevention coronary heart disease.
Because the harm of hyperlipidemia more and more comes into one's own, the product of blood fat reducing is more and more thereupon.Western medicine such as blood lipid-lowering medicine simvastatin commonly used, lovastatin all have certain side effect, and Chinese medicine phase antithetical phrase Western medicine toxic and side effects is much smaller, and part Chinese medicine be medicine be again food, can be developed to health food, be suitable for taking for a long time, effect is better.At present, though domestic blood lipid regulation health food is more, generally acknowledge that the outstanding effect product does not almost have.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of blood fat reducing function clear and definite, and the obvious results natural plant extracts health product.
Blood fat reducing health products disclosed by the invention contains the active ingredient that Fructus Crataegi extract, wolfberry fruit extract, Rhizoma Alismatis extract and soybean extract are formed, weight ratio between them is a Fructus Crataegi extract: wolfberry fruit extract: Rhizoma Alismatis extract: soybean extract=(60-180): (40-120): (25-75): (10-30), this active ingredient extract can directly be made various oral formulations, also can add the pharmaceutic adjuvant of various ratios or other Chinese medicine extract, Western medicine is formed various oral formulations; The active ingredient extractive total flavone is counted 50-160g/kg with hyperin (Hyporoside) in the oral formulations.
Oral formulations of the present invention is meant medically acceptable all kinds of preparations, as tablet, capsule, granule, oral liquid etc.
Pharmaceutic adjuvant of the present invention is excipient commonly used, correctives, disintegrating agent etc.
Another technical problem to be solved by this invention is the preparation method that discloses above-mentioned blood fat reducing health products.
The preparation method of blood fat reducing health products disclosed by the invention comprises the following steps:
1. the preparation of active ingredient extract
(1) preparation of Fructus Crataegi extract
Get the Fructus Crataegi medicinal part, be ground into coarse powder, decoct with water secondary, add 10 times of amounts of water for the first time, decocted 2 hours, add 8 times of amounts of water the second time, decocted collecting decoction 1 hour.Extracting solution is by macroporous resin (D
101Type) post, the washing decontamination is used 75% ethanol elution then, to there not being the flavone characteristic reaction, concentrates, 60-70 ℃ of drying, 2-4 hour, promptly.
(2) preparation of Rhizoma Alismatis extract
Get the Rhizoma Alismatis decoction pieces, be ground into coarse powder,, reclaim ethanol with 8 times of amount 80% alcohol reflux 4 hours, 60-70 ℃ of drying, 2-4 hour, promptly.
(3) preparation of soybean extract
The extracting degreasing Semen sojae atricolor is ground into coarse powder, with 70% ethanol extraction 2 times, adds 10 times of amounts of 70% ethanol, adds 8 times of amounts of 70% ethanol for the second time for the 1st time.Each 2 hours, reclaim ethanol, behind the dilute with water, by macroporous resin (D
101Type) post, 80% ethanol elution is used in the water washing removal of impurity then, to there not being the flavone characteristic reaction, reclaims ethanol, volatilize, 60-70 ℃ of drying, 2-4 hour, promptly.
(4) preparation of wolfberry fruit extract
Get Fructus Lycii, decoct with water secondary, add 8 times of amounts of water for the first time and decocted 2 hours, add 6 times of amounts of water for the second time and decocted 1.5 hours, collecting decoction concentrates, and adding ethanol is 70% to containing the alcohol amount, leaves standstill, and filters, and volatilizes ethanol, gets 60-70 ℃ of drying of precipitation, and 3-5 hour, promptly.
2. the preparation of oral formulations
Measure Fructus Crataegi extract, wolfberry fruit extract, Rhizoma Alismatis extract and soybean extract by prescription, mix homogeneously, make tablet, capsule, granule and oral liquid according to a conventional method, make in the preparation flavones content count 50-160g/Kg with hyperin (Hyporoside).
A technical problem more to be solved by this invention is to disclose the application of above-mentioned oral formulations in the preparation blood fat reducing health products.
Blood fat reducing health products taking dose disclosed by the invention is counted 1.2-2.4g/ days with active component extract, and Time of Administration is more than one month.
The Fructus Crataegi extract master that the present invention adopts contains Fructus Crataegi flavone by regulating lipid metabolism, and main triglyceride reducing has the effect of cholesterol reducing, low density lipoprotein, LDL and raising high density lipoprotein simultaneously; Rhizoma Alismatis extract contains Rhizoma Alismatis terpene alcohol, reduces the synthetic of endogenous lipid, reduces T-CHOL in the blood plasma, suppresses intrahepatic fat and piles up; The wolfberry fruit extract master contains lycium barbarum polysaccharide, has the transhipment and the excretory effect that promote lipid, significantly the effect of cholesterol reducing and triglyceride; The soybean extract master contains soybean isoflavone and has effect for reducing blood fat.More than four kinds of extracts mix by a certain percentage, from reduce the endogenous lipid synthetic, promote the transhipment and the many-sides such as drainage, adjusting lipid metabolism of lipid to play effect for reducing blood fat.
Carry out relevant efficacy test with blood fat reducing oral formulations of the present invention:
Give high fat nutrient fodder to SD kind rat every day, give preparation of the present invention 5 times of recommended amounts 0.1g/kgb.w. simultaneously respectively, 10 times of recommended amounts 0.2g/kgb.w., three dosage preventions of 30 times of recommended amounts 0.6g/kgb.w. animal hyperlipemia, gave capsule of the present invention totally 30 days, the result obtains:
1.0.6g/kgb.w. the serum total cholesterol of dosage group (TC) level reduces, the reduction amplitude is 20.31%, compares with high fat matched group, and difference has significance meaning (P＜0.05).
2.0.6g/kgb.w. the serum triglycerides of dosage group (TG) level and high fat matched group are relatively, the reduction amplitude is 32.03%, and difference has significance meaning (P＜0.05).
Through experiment confirm: product of the present invention has the health care of blood lipid regulation, can suppress exogenous lipid absorption, triglyceride reducing and cholesterol are synthetic, high density lipoprotein increasing, promote cholesterol transport, reduce atherogenic index, avoid a series of organ diseases such as the cardiovascular and cerebrovascular vessel that cause because of hyperlipemia and Liver and kidney.
Oral formulations of the present invention proves safety non-toxic through the safety toxicological test:
1. its mouse oral clothes acute toxicity test, male and female mice LD
50＞21.50g/kgb.w., submitted sample belong to nontoxic level material.
2. mouse bone marrow cells micronucleus test
1.25-10g/kgb.w. dosage, the micronucleus test result is negative, and somatic cell is not had mutagenesis.
3. mouse sperm distortion test
2.5-10g/kgb.w. dosage, the spermatic aberration test result is negative, and sexual cell is not had mutagenesis.
4.Ames test
0.5-5000 no matter add or do not add the S9 mixture in each dosage of μ g/ ware, result of the test does not find that this product has direct or indirect mutagenic action.
Along with the raising of people's living standard, quality of life is had higher requirement, particularly self health care is more and more paid attention to.Blood fat reducing health products safety non-toxic of the present invention, and have good effect for reducing blood fat, with every year for the health product that the hyperlipidemia crowd more than 1,000,000 provides a kind of exact efficacy, have good social benefit and economic benefit.
The specific embodiment
The preparation of embodiment 1 active component extract
(1) preparation of Fructus Crataegi extract
Get the Fructus Crataegi medicinal part, be ground into coarse powder, decoct with water secondary, add 10 times of amounts of water for the first time, decocted 2 hours, add 8 times of amounts of water the second time, decocted collecting decoction 1 hour.Extracting solution is by macroporous resin (D
101Type) post, the washing decontamination is used 75% ethanol elution then, to there not being the flavone characteristic reaction, concentrates, 60-70 ℃ of drying, 3 hours, promptly.
(2) preparation of Rhizoma Alismatis extract
Get the Rhizoma Alismatis decoction pieces, be ground into coarse powder,, reclaim ethanol with 8 times of amount 80% alcohol reflux 4 hours, 60-70 ℃ of drying, 4 hours, promptly.
(3) preparation of soybean extract
The extracting degreasing Semen sojae atricolor is ground into coarse powder, with 70% ethanol extraction 2 times, adds 10 times of amounts of 70% ethanol, adds 8 times of amounts of 70% ethanol for the second time for the 1st time.Each 2 hours, reclaim ethanol, behind the dilute with water, by macroporous resin (D
101Type) post, 80% ethanol elution is used in the water washing removal of impurity then, to there not being the flavone characteristic reaction, reclaims ethanol, volatilize, 60-70 ℃ of drying, 4 hours, promptly.
(4) preparation of wolfberry fruit extract
Get Fructus Lycii, decoct with water secondary, add 8 times of amounts of water for the first time and decocted 2 hours, add 6 times of amounts of water for the second time and decocted 1.5 hours, collecting decoction concentrates, and adding ethanol is 70% to containing the alcohol amount, leaves standstill, and filters, and volatilizes ethanol, gets 60-70 ℃ of drying of precipitation, and 5 hours, promptly
The preparation of embodiment 2 capsules
Prescription: Fructus Crataegi extract: wolfberry fruit extract: Rhizoma Alismatis extract: soybean extract=60: 60: 75: 30
Extract each active component by the method for embodiment 1, mix with the recipe quantity proportioning, recording hyperin content is 59.4g/kg, then with the dextrin mixing of 0.33 times of amount, in the glue shell of packing into promptly, every capsules 0.3g.
The preparation of embodiment 3 tablets
Prescription:
Fructus Crataegi extract: wolfberry fruit extract: Rhizoma Alismatis extract: soybean extract=180: 40: 25: 10
Extract each active component by the method for embodiment 1, mix with the recipe quantity proportioning, recording hyperin content is 120g/kg, then with the dextrin mixing of 0.2 times of amount, and one-step palletizing, tabletting promptly gets tablet, the 0.3g/ sheet.
The preparation of embodiment 4 granules
Prescription: Fructus Crataegi extract: wolfberry fruit extract: Rhizoma Alismatis extract: soybean extract=120: 80: 50: 20
Extract each active component by the method for embodiment 1, mix with the recipe quantity proportioning, recording hyperin content is 80.5g/kg, then with the dextrin mixing of 0.11 times of amount, and one-step palletizing, packing is promptly.
Embodiment 5 uses
With capsule 0.3g/ grain of the present invention, take twice every day, to take one month, hyperlipemia all takes an evident turn for the better, and experimental result is as follows:
| Sequence number | Sex | Age | Cholesterol mmol/L (3.10-5.17) | Triglyceride mmol/L (0.56-2.30) | High-density lipoprotein mmol/L (0.90-1.50) | Low-density lipoprotein mmol/L (0.00-3.36) | |
| 1 | The man | 54 | Before taking | 3.79 | 2.43 | 1.33 | 2.40 |
| After taking | 4.23 | 1.26 | 1.45 | -- | |||
| 2 | The woman | 60 | Before taking | 5.32 | 3.09 | 1.23 | 3.20 |
| After taking | 5.14 | 1.34 | 1.47 | -- | |||
| 3 | The man | 34 | Before taking | 5.23 | 1.85 | 0.95 | 3.70 |
| After taking | 5.09 | 1.57 | 1.03 | -- | |||
| 4 | The man | 32 | Before taking | 3.94 | 2.44 | 1.32 | 2.60 |
| After taking | 4.17 | 1.04 | 1.44 | -- | |||
| 5 | The man | 29 | Before taking | 5.56 | 2.74 | 1.50 | 3.60 |
| After taking | 5.61 | 1.37 | 1.47 | 3.00 | |||
| 6 | The man | 66 | Before taking | 6.60 | 2.05 | 1.50 | 4.70 |
| After taking | 5.82 | 0.92 | 1.21 | 4.10 | |||
| 7 | The woman | 59 | Before taking | 6.20 | 2.57 | 1.50 | 4.60 |
| After taking | 6.45 | 2.00 | 1.42 | -- | |||
| 8 | The man | 35 | Before taking | 5.68 | 1.88 | 1.50 | 4.30 |
| After taking | 4.87 | 1.37 | 0.91 | 3.10 | |||
Claims (4)
1, a kind of health product with blood lipid regulation effect is characterized in that these health product are that Fructus Crataegi extract, wolfberry fruit extract, Rhizoma Alismatis extract and soybean extract and pharmaceutic adjuvant are formed by active component; Weight ratio between each component of active component is a Fructus Crataegi extract: wolfberry fruit extract: Rhizoma Alismatis extract: soybean extract=60-180: 40-120: 25-75: 10-30;
Fructus Crataegi extract wherein, wolfberry fruit extract, Rhizoma Alismatis extract, soybean extract is made by following method:
(1) preparation of Fructus Crataegi extract
Get the Fructus Crataegi medicinal part, be ground into coarse powder, decoct with water secondary, collecting decoction; Extracting solution passes through D
101The type macroporous resin column, the washing decontamination is used 75% ethanol elution then, to there not being the flavone characteristic reaction, concentrates, drying, promptly;
(2) preparation of Rhizoma Alismatis extract
Get the Rhizoma Alismatis decoction pieces, be ground into coarse powder, use 80% alcohol reflux, reclaim ethanol, drying, promptly;
(3) preparation of soybean extract
The extracting degreasing Semen sojae atricolor is ground into coarse powder, with 70% ethanol extraction 2 times, reclaims ethanol, behind the dilute with water, passes through D
101The type macroporous resin column, 80% ethanol elution is used in the water washing removal of impurity then, to there not being the flavone characteristic reaction, reclaims ethanol, volatilize, drying, promptly;
(4) preparation of wolfberry fruit extract
Get Fructus Lycii, decoct with water secondary, collecting decoction, concentrated, adding ethanol is 70% to containing the alcohol amount, leaves standstill, and filters, and volatilizes ethanol, gets the precipitation drying, promptly.
2, a kind of health product with blood lipid regulation effect as claimed in claim 1, the dosage form that it is characterized in that these health product is medically acceptable all kinds of tablets, capsule, granule and oral liquid.
3, a kind of preparation method with Chinese medicine health care product of blood lipid regulation effect as claimed in claim 1 is characterized in that wherein oral formulations is made by following method:
Get Fructus Crataegi extract, wolfberry fruit extract, Rhizoma Alismatis extract and soybean extract by said ratio, mix homogeneously makes in the active ingredient general flavone content count 50-160g/Kg with hyperin, makes tablet, capsule, granule and oral liquid according to a conventional method.
4, the application of a kind of health product as claimed in claim 1 in preparation blood lipid regulation health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01113266 CN1216613C (en) | 2001-07-05 | 2001-07-05 | Health-care product capable of regulating blood-lipid and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01113266 CN1216613C (en) | 2001-07-05 | 2001-07-05 | Health-care product capable of regulating blood-lipid and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1394614A CN1394614A (en) | 2003-02-05 |
| CN1216613C true CN1216613C (en) | 2005-08-31 |
Family
ID=4660001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01113266 Expired - Lifetime CN1216613C (en) | 2001-07-05 | 2001-07-05 | Health-care product capable of regulating blood-lipid and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1216613C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325089C (en) * | 2005-02-06 | 2007-07-11 | 杭州鑫富药业有限公司 | Chinese patent medicine on health food composition and its use |
| CN102524795A (en) * | 2010-12-17 | 2012-07-04 | 武汉金肽堂生物科技有限公司 | Bacillus natto and application thereof in preparing thrombolytic healthcare food |
| CN102872306B (en) * | 2012-09-25 | 2014-04-09 | 深圳市安美信生物医药科技有限公司 | Compound selenium Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN104172167A (en) * | 2014-08-20 | 2014-12-03 | 陕西华州医药生物工程有限公司 | Cholesterol-lowering functional food and preparation method thereof |
| CN111184185A (en) * | 2020-01-15 | 2020-05-22 | 宁夏医科大学 | Composition with blood fat regulating effect and preparation method and application thereof |
-
2001
- 2001-07-05 CN CN 01113266 patent/CN1216613C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1394614A (en) | 2003-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1236792C (en) | Brain active effect matter for prevention and curing encephalopathy and developing intelligence and its preparation method | |
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN101181351B (en) | Chinese medicine composition for resisting tiredness and reinforcing immune as well as method of making the same | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN100558347C (en) | Ginseng-astragalus dispersion tablet formulation and preparation technology thereof | |
| CN106214773A (en) | A kind of to chemical liver injury compositions having assistant protection function and preparation method thereof | |
| CN1883623A (en) | A blood fat-decreasing compound Chinese medicine and preparation method thereof | |
| CN1216613C (en) | Health-care product capable of regulating blood-lipid and its preparation method | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1872134A (en) | Composition of bitter melon polysaccharide for reducing blood sugar, and preparation method | |
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN114470042B (en) | Composition for preventing and treating liver injury of animals as well as preparation method and application thereof | |
| CN1709415A (en) | Asparagus extract and its preparing method | |
| CN1067258C (en) | Medicinal preparation with extractive from yangtao root and preparing process thereof | |
| CN1709462A (en) | Ginseng-astragalus capsule formulation and its preparing process | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN101385783A (en) | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN1250244C (en) | Composition for preventing and treating hyperlipidemia | |
| CN106262805A (en) | A kind of for compositions preventing and treating hyperlipidemia and preparation method thereof | |
| CN1239159C (en) | Medicine composition for reducing blood fat | |
| CN1686112A (en) | Use of cnidicin and preparation used for treating fatty liver | |
| CN1672719A (en) | Application of fleece flower root in preparing medicine for treating fatty liver | |
| CN1186030C (en) | Composition for losing weight of mammal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TAITAI MEDICINE CO., LTD. Free format text: FORMER OWNER: SHENZHENG TAITAN MEDICINE INDUSTRY CO., LTD. Effective date: 20030514 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030514 Address after: 518057 Nanshan Fifth Industrial Zone, Guangdong, Shenzhen Applicant after: Shenzhen Taitai Pharmaceutical Industry Co., Ltd. Address before: 518008, Guangdong, Shenzhen province Shennan East Road, No. 5002 Hing Plaza Plaza, Wang commercial center commercial building 23 floor Applicant before: Shenzhen Taitai Pharmaceutical Industry Co. Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050831 |
|
| CX01 | Expiry of patent term |